Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00125320 · ClinicalTrials.gov registry record · Phase 3

Response to RSD1235 Compared to Placebo in Subjects With Atrial Arrhythmia After Heart Surgery

A Phase 3 study, sponsored by Astellas Pharma.

Completed
Registry status
Phase 3
Development phase
190
Enrollment target

NCT00125320: Completed Phase 3 study, sponsored by Astellas Pharma.

NCT00125320 is a Phase 3 study that has completed, run by Astellas Pharma. The registered enrollment target is 190 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00125320, a Phase 3 study, has completed, sponsored by Astellas Pharma.

COMPLETED
Registry status
Phase 3
Development phase
190 participants
Enrollment target

Study Summary

The purpose of this study is to demonstrate the safety and efficacy of RSD1235 compared to placebo in the conversion of atrial arrhythmia to sinus rhythm in subjects following valvular and/or coronary artery bypass graft surgery.

Interventions

  • DRUG RSD1235

Trial Details

FieldValue
Enrollment Target 190 participants
Start Date 2004-06
Est. Completion 2007-02
Phase Phase 3
Astellas Pharma

165 total trials

What the finished NCT00125320 record still lists

NCT00125320 is an interventional study that assigns participants to a tested intervention. The registered 190 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (75% lower).

The record links to 0 conditions, and to 1 intervention - of which RSD1235 is the first listed.

NCT00125320 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00125320 about?

NCT00125320 is a clinical study titled "Response to RSD1235 Compared to Placebo in Subjects With Atrial Arrhythmia After Heart Surgery". The purpose of this study is to demonstrate the safety and efficacy of RSD1235 compared to placebo in the conversion of atrial arrhythmia to sinus rhythm in subjects following valvular and/or coronary artery bypass graft surgery.

What is the current status of trial NCT00125320?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 190 participants. The study started on 2004-06. Estimated completion is 2007-02.

What interventions are being tested in trial NCT00125320?

The interventions under investigation include: RSD1235 (DRUG).

Who is sponsoring clinical trial NCT00125320?

This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00125320's enrollment target sits among peer trials

190 1402nd of 2000 higher than 593 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03257033 · 190 participants · Phase 3

    Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC

  • NCT03642028 · 190 participants · Phase 4

    Suvorexant: A Dual Orexin Receptor Antagonist for Treating Sleep Disturbance in Posttraumatic Stress

  • NCT04015609 · 190 participants · NA

    Psychotherapy Intervention for Latinos With Advanced Cancer

  • NCT04284397 · 190 participants · Early Phase 1

    Identification of Critical Thermal Environments for Aged Adults

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00125320, the US trial registry maintained by the National Library of Medicine. NCT00125320 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.